Tuesday, March 17, 2026 3/17/2026

Reprogramming fibroblasts embryonic origins to overcome skin fibrosis and scarring.

Award Number: R01DE032677
ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2023
PERIOD OF PERFORMANCE END DATE: 03/31/2028

Group Awards By:

View Award Description

Reprogramming fibroblasts embryonic origins to overcome skin fibrosis and scarring. - 7. Project Summary/Abstract Adult human skin heals by developing fibrotic scar tissue, which can result in devastating disfigurement, growth restriction, and permanent functional loss. Despite a plethora of clinical options, no current treatment strategies successfully prevent or reverse this fibrotic process, and over $20 billion is spent each year in the United States for the treatment of scars and their sequelae. Fibroblasts are recognized as the primary cell responsible for depositing extracellular matrix and causing skin fibrosis. However, progress towards the development of treatments aimed at reducing scars is impeded by a limited understanding of specific fibroblast subpopulations responsible for regenerative healing. We have observed that neural crest-derived facial skin wounds heal with less fibrosis than mesoderm-derived scalp wounds, somite-derived dorsal wounds, and lateral plate mesoderm- derived ventral wounds. Furthermore, through single cell RNA sequencing, we have identified that neural crest- derived facial fibroblasts promote regeneration following skin injury through a Robo2-EID1-EP300 axis, and bromodomain inhibition of EP300 guides fibroblasts to heal with reduced skin scarring. In this proposal, we examine the potential of the Robo2-Eid1-EP300 axis and EP300 bromodomain inhibition to guide dorsal scarring fibroblasts to heal with reduced fibrosis. We will employ both cell transplantation and CRISPR-Cas9 approaches, using histology, immunohistochemistry, transcriptional analysis, and flow cytometry to evaluate the regenerative capacity of Robo2+ fibroblasts within wounds. We will then determine the role of EP300 interacting inhibitor of differentiation 1 (EID1) in regulating Robo2 fibroblast activity in skin wounds. We will employ cell transplantation and CRISPR-Cas9 approaches to robustly determine whether activation of EID1 promotes regeneration of dorsal wounds to heal like facial wounds. Finally, having established that the Robo2-EID1-EP300 axis is responsible for regenerative healing, we will inhibit EP300 signaling using both small molecule and transgenic approaches to guide facial-like regenerative healing in dorsal wounds. Our ultimate translational goal is to develop therapeutics that target fibrogenic wound cell dynamics to promote regenerative healing. Collectively, the proposed work will significantly enhance our understanding of the key molecular and cellular determinants of cutaneous scarring, shedding light on the contributions of Robo2-EID1-EP300 activity in wound repair and scarring, and inform the development of novel anti-scarring therapeutics.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $355,466 )
2026	2026	THE LELAND STANFORD JUNIOR UNIVERSITY	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Oral Diseases and Disorders Research	000	4	3/5/2026	NON-COMPETING CONTINUATION	$355,466
														Subtotal = $355,466

Issue Date FY: 2025 ( Subtotal = $355,229 )
2025	2025	THE LELAND STANFORD JUNIOR UNIVERSITY	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Oral Diseases and Disorders Research	001	3	5/8/2025	NON-COMPETING CONTINUATION	$35,522
2025	2025	THE LELAND STANFORD JUNIOR UNIVERSITY	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Oral Diseases and Disorders Research	000	3	3/6/2025	NON-COMPETING CONTINUATION	$319,707
														Subtotal = $355,229

Issue Date FY: 2024 ( Subtotal = $347,899 )
2024	2024	THE LELAND STANFORD JUNIOR UNIVERSITY	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Oral Diseases and Disorders Research	001	2	6/18/2024	NON-COMPETING CONTINUATION	$28,399
2024	2024	THE LELAND STANFORD JUNIOR UNIVERSITY	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Oral Diseases and Disorders Research	000	2	3/26/2024	NON-COMPETING CONTINUATION	$319,500
														Subtotal = $347,899

Issue Date FY: 2023 ( Subtotal = $355,412 )
2023	2023	THE LELAND STANFORD JUNIOR UNIVERSITY	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Oral Diseases and Disorders Research	000	1	2/23/2023	NEW	$355,412
														Subtotal = $355,412

Grand Total All Awards = $1,414,006

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Reprogramming fibroblasts embryonic origins to overcome skin fibrosis and scarring.

Award Number: R01DE032677

ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2023

PERIOD OF PERFORMANCE END DATE: 03/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer